TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05612282

Intervention type: DIAGNOSTIC_TEST
Intervention: body composition analysis
Description: A body composition analysis was performed using the bioelectroimpedance method using the Maltron BioScan 920-2 analyzer

Intervention type: OTHER
Intervention: anthropometric measurements
Description: An assessment of the status of nutrition based on anthropometric measurements was carried out.

Intervention type: OTHER
Intervention: anthropometric measurements
Description: An assessment of the status of nutrition based on anthropometric measurements was carried out.

Intervention type: OTHER
Intervention: anthropometric measurements
Description: An assessment of the status of nutrition based on anthropometric measurements was carried out.

Intervention type: OTHER
Intervention: anthropometric measurements
Description: An assessment of the status of nutrition based on anthropometric measurements was carried out.

Intervention type: OTHER
Intervention: anthropometric measurements
Description: An assessment of the status of nutrition based on anthropometric measurements was carried out.

Intervention type: OTHER
Intervention: anthropometric measurements
Description: An assessment of the status of nutrition based on anthropometric measurements was carried out.

Intervention type: OTHER
Intervention: Interview questionnaire
Description: An interview questionnaire concerning the duration of obesity and past diseases was collected. Moreover, the diet and nutritional status were assessed.

Intervention type: OTHER
Intervention: Interview questionnaire
Description: An interview questionnaire concerning the duration of obesity and past diseases was collected. Moreover, the diet and nutritional status were assessed.

Intervention type: OTHER
Intervention: Interview questionnaire
Description: An interview questionnaire concerning the duration of obesity and past diseases was collected. Moreover, the diet and nutritional status were assessed.

Intervention type: OTHER
Intervention: Interview questionnaire
Description: An interview questionnaire concerning the duration of obesity and past diseases was collected. Moreover, the diet and nutritional status were assessed.

Intervention type: OTHER
Intervention: Interview questionnaire
Description: An interview questionnaire concerning the duration of obesity and past diseases was collected. Moreover, the diet and nutritional status were assessed.
Study: NCT04779333

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard BMT
Description: Weekly BMT groups sessions which follow the Barkley curriculum
Study: NCT04219930

Intervention type: DIAGNOSTIC_TEST
Intervention: Expression of nucleotide protein -3
Description: Expression of nucleotide protein -3 will be measured in serum by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Expression of nucleotide protein -3
Description: Expression of nucleotide protein -3 will be measured in serum by ELISA
Study: NCT05612282

Intervention type: OTHER
Intervention: Interview questionnaire
Description: An interview questionnaire concerning the duration of obesity and past diseases was collected. Moreover, the diet and nutritional status were assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical parameters
Description: The concentrations of the following parameters were determined from the blood serum: fasting glucose, fasting insulin, total cholesterol, LDL cholesterol fraction, HDL cholesterol fraction, triglycerides, C-reactive protein (CRP), uric acid, creatinine, and aminotrasferases: alanine (ALT) and aspartate (AST). On the basis of fasting glucose and fasting insulin, the HOMA - IR insulin resistance index was calculated.

Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical parameters
Description: The concentrations of the following parameters were determined from the blood serum: fasting glucose, fasting insulin, total cholesterol, LDL cholesterol fraction, HDL cholesterol fraction, triglycerides, C-reactive protein (CRP), uric acid, creatinine, and aminotrasferases: alanine (ALT) and aspartate (AST). On the basis of fasting glucose and fasting insulin, the HOMA - IR insulin resistance index was calculated.
Study: NCT00486759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Study: NCT05216848

Intervention type: OTHER
Intervention: Wijma Delivery Expectancy Questionnaire
Description: Simple questionaire identifying the level of fear of childbirth in pregnancy

Intervention type: OTHER
Intervention: Clinical data collection
Description: Collection of the standard clinical data during hospitalization

Intervention type: OTHER
Intervention: Clinical data collection
Description: Collection of the standard clinical data during hospitalization
Study: NCT00486759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was administered at a dose of 375 mg/m\^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Study: NCT01274741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creating Change (CC)
Description: Creating Change is a past-focused, integrated, cognitive-behavioral therapy for PTSD/SUD. It has 17 topics, which in this study were delivered in weekly one-hour sessions, in individual format. The treatment explores how PTSD and SUD arose and interacted across the patient's life, including constructing a narrative of its meaning, processing associated emotions and memories, and exploring themes related to these.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Seeking Safety (SS)
Description: Seeking Safety is a present-focused, evidence-based cognitive-behavioral therapy for integrated treatment of patients with PTSD/SUD. It is a cognitive-behavioral therapy comprising 25 topics, each a coping skill relevant to both disorders. In this study 17 of the 25 topics were conducted, one per weekly, one-hour, individual session.
Study: NCT00486759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab was administered at a dose of 375 mg/m\^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m\^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m\^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m\^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m\^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Study: NCT01181180

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: water consumption
Description: The effect of water consumption on postural stability of old adults (65 years old and over) will be measured using RCT study design

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water consumption
Description: The effect of water consumption on postural stability of old adults (65 years old and over) will be measured using RCT study design
Study: NCT03635294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: combining genomics, transcriptomics, metabolomics and morphological analyses performed on induced pluripotent stem cell (iPSC)-derived neural cells
Study: NCT05612282

Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical parameters
Description: The concentrations of the following parameters were determined from the blood serum: fasting glucose, fasting insulin, total cholesterol, LDL cholesterol fraction, HDL cholesterol fraction, triglycerides, C-reactive protein (CRP), uric acid, creatinine, and aminotrasferases: alanine (ALT) and aspartate (AST). On the basis of fasting glucose and fasting insulin, the HOMA - IR insulin resistance index was calculated.
Study: NCT05250336

Intervention type: OTHER
Intervention: Observational Study
Description: Assessment of Prognostic and Predictive value of Tumor-Infiltrating Lymphocytes and Programmed cell Death - Ligand 1 in Breast cancer
Study: NCT04313543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose and Longan syrup
Description: Volunteers take 50 g of glucose in 250 ml of water in 5 minutes. Then, they take 50g of longan syrup in 250 ml of water in 5 minutes
Study: NCT00573339

Intervention type: OTHER
Intervention: Cardiac MRI
Description: up to 3 Cardiac MRI scans per participant in 1-4 months
Study: NCT01063036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets, Oral, 1 mg, once daily, 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Tablets, Oral, 300 mg, once daily, 96 weeks
Study: NCT02293018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% (w/w) MTC896 Gel Once Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% (w/w) MTC896 Gel Twice Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% (w/w) MTC896 Gel Once Daily
Study: NCT06336486

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent pneumatic compression +pregabalin group
Description: The investigators divided the patients into two equal groups , some of the patients were given an intermittent pneumatic compression program at a pressure of 35 mmhg for 30 min to the lower extremity for 10 days of extreme alternation in our clinic and pregabalin treatment was continued.

Intervention type: OTHER
Group type: OTHER
Intervention: pregabalin group
Description: only pregabalin treatment was continued.
Study: NCT00178399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Study: NCT02814643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benralizumab Placebo
Description: Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seasonal influenza virus vaccine
Description: Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Seasonal influenza virus vaccine
Description: Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
Study: NCT02195713

Intervention type: DEVICE
Intervention: Accuryn
Description: Accuryn is a novel electronic urine output monitor
Study: NCT02356549

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMR Tailoring
Description: Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMR Tailoring
Description: Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMR Tailoring
Description: Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMR Tailoring
Description: Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey Tailoring
Description: Survey that will use standardized, psycho-metrically sound measures to gather information about patients, including their levels of trust in medical research and preferences for information and decision involvement. The survey augmented by their EMR data will be used to develop a level of tailored messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey Tailoring
Description: Survey that will use standardized, psycho-metrically sound measures to gather information about patients, including their levels of trust in medical research and preferences for information and decision involvement. The survey augmented by their EMR data will be used to develop a level of tailored messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician Involvement
Description: Prior to the consultation, physicians of patients will receive a summary of patients' tailored message brochure from the Research Assistant (RA) and included in the patient's notes. At the conclusion of the consultation, the RA will ask the oncologist whether or not a clinical trial was discussed and whether or not they read the patients brochure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician Involvement
Description: Prior to the consultation, physicians of patients will receive a summary of patients' tailored message brochure from the Research Assistant (RA) and included in the patient's notes. At the conclusion of the consultation, the RA will ask the oncologist whether or not a clinical trial was discussed and whether or not they read the patients brochure.
Study: NCT04847219

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Professional flash glucose mornitoring
Description: Subjects will use Professional flash glucose mornitoring once a month for 3 months.
Study: NCT05612282

Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical parameters
Description: The concentrations of the following parameters were determined from the blood serum: fasting glucose, fasting insulin, total cholesterol, LDL cholesterol fraction, HDL cholesterol fraction, triglycerides, C-reactive protein (CRP), uric acid, creatinine, and aminotrasferases: alanine (ALT) and aspartate (AST). On the basis of fasting glucose and fasting insulin, the HOMA - IR insulin resistance index was calculated.

Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical parameters
Description: The concentrations of the following parameters were determined from the blood serum: fasting glucose, fasting insulin, total cholesterol, LDL cholesterol fraction, HDL cholesterol fraction, triglycerides, C-reactive protein (CRP), uric acid, creatinine, and aminotrasferases: alanine (ALT) and aspartate (AST). On the basis of fasting glucose and fasting insulin, the HOMA - IR insulin resistance index was calculated.

Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical parameters
Description: The concentrations of the following parameters were determined from the blood serum: fasting glucose, fasting insulin, total cholesterol, LDL cholesterol fraction, HDL cholesterol fraction, triglycerides, C-reactive protein (CRP), uric acid, creatinine, and aminotrasferases: alanine (ALT) and aspartate (AST). On the basis of fasting glucose and fasting insulin, the HOMA - IR insulin resistance index was calculated.

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary fitness test
Description: Cardiopulmonary fitness was assessed using the Modified Bruce protocol

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary fitness test
Description: Cardiopulmonary fitness was assessed using the Modified Bruce protocol
Study: NCT04847219

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personal flash glucose mornitoring
Description: Subjects will use Personal flash glucose mornitoring once a month for 3 months.
Study: NCT02391207

Intervention type: PROCEDURE
Intervention: Hepatic vein-sparing hepatectomy
Description: HV detachment, partial resection and section on the basis of HV-CLM relationship
Study: NCT05612282

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary fitness test
Description: Cardiopulmonary fitness was assessed using the Modified Bruce protocol

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary fitness test
Description: Cardiopulmonary fitness was assessed using the Modified Bruce protocol

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary fitness test
Description: Cardiopulmonary fitness was assessed using the Modified Bruce protocol

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary fitness test
Description: Cardiopulmonary fitness was assessed using the Modified Bruce protocol

Intervention type: OTHER
Intervention: nutritional interview
Description: A 7-day nutrition interview was collected. The supply of energy, protein (including amino acids), fat (including fatty acids), carbohydrates, dietary fiber, vitamins and minerals in the usual diet was assessed.

Intervention type: OTHER
Intervention: nutritional interview
Description: A 7-day nutrition interview was collected. The supply of energy, protein (including amino acids), fat (including fatty acids), carbohydrates, dietary fiber, vitamins and minerals in the usual diet was assessed.
Study: NCT02958345

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Vaccination with one dose of Zostavax per Zostavax package insert

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of 0.65 mL of sterile normal saline
Study: NCT05612282

Intervention type: OTHER
Intervention: nutritional interview
Description: A 7-day nutrition interview was collected. The supply of energy, protein (including amino acids), fat (including fatty acids), carbohydrates, dietary fiber, vitamins and minerals in the usual diet was assessed.

Intervention type: OTHER
Intervention: nutritional interview
Description: A 7-day nutrition interview was collected. The supply of energy, protein (including amino acids), fat (including fatty acids), carbohydrates, dietary fiber, vitamins and minerals in the usual diet was assessed.
Study: NCT02416076

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera Treatment at EL2
Description: Focused ultrasound energy delivered below the surface of the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera Treatment at EL2
Description: Focused ultrasound energy delivered below the surface of the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera Treatment at EL4
Description: Focused ultrasound energy delivered below the surface of the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera Treatment at EL4
Description: Focused ultrasound energy delivered below the surface of the skin.
Study: NCT04887103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot water application
Description: Pregnant women will apply hot water to their legs before going to sleep for a week.
Study: NCT02416076

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera Treatment at EL4
Description: Focused ultrasound energy delivered below the surface of the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera Treatment at EL4
Description: Focused ultrasound energy delivered below the surface of the skin.
Study: NCT03919864

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CONNECT Intervention
Description: Participants will be included in a multi-component e-tool with brief educational videos, an assessment of multidimensional supportive care needs, a tailored resource list and an optional automated referral to a caregiver navigator. Two weeks after baseline participants will receive re-education and an optional referral.
Study: NCT01848054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone sublingual tablets
Description: Advanced-formulation buprenorphine/naloxone sublingual tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone sublingual tablets
Description: Advanced-formulation buprenorphine/naloxone sublingual tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine sublingual tablets
Study: NCT00792233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Withdrawal of anti-TNF therapy
Description: Anti-TNF therapy will be discontinued at the third visit in children who demonstrate persistent inactive disease for at least 6 months.
Study: NCT04044209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: The IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle.
Study: NCT03580382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib daily Until PD
Description: 1.0 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib daily Until PD
Description: 1.0 mg daily
Study: NCT04435626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: For participants with an eGFR ≤60 mL/min/1.73 m\^2: Starting dose is 10 mg OD and maximum dose 20 mg OD.~For participants with an eGFR \>60 mL/min/1.73 m\^2: Starting dose is 20 mg OD and maximum dose 40 mg OD. Finerenone is administered orally as immediate release tablets.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching BAY94-8862 are administered orally.
Study: NCT01936558

Intervention type: OTHER
Intervention: Far infrared ray to the sole
Description: exposure 40-minute far infrared ray to the sole for each person/amputee.

Intervention type: OTHER
Intervention: Far infrared ray to the sole
Description: exposure 40-minute far infrared ray to the sole for each person/amputee.